NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RVTY

Revvity Inc

Jul 11 • 04:00PM ET

101.50

Dollar change -0.90
Percentage change -0.88	%

Healthcare • Diagnostics & Research • USA • NYSE

Peers: TMO DHR A MTD BIO WAT BRKR ILMN

| Held by: VTI VOO VB VBR RSP SPY IVV TCAF XLV IWR

Scroll to Statements

Index	S&P 500	P/E	40.13	EPS (ttm)	2.53	Insider Own	0.42%	Shs Outstand	119.41M	Perf Week	0.19%
Market Cap	11.96B	Forward P/E	18.54	EPS next Y	5.47	Insider Trans	-3.46%	Shs Float	117.37M	Perf Month	5.45%
Enterprise Value	14.15B	PEG	5.24	EPS next Q	1.14	Inst Own	98.28%	Short Float	5.06%	Perf Quarter	0.16%
Income	309.55M	P/S	4.32	EPS this Y	0.47%	Inst Trans	3.03%	Short Ratio	4.74	Perf Half Y	-12.95%
Sales	2.77B	P/B	1.59	EPS next Y	11.20%	ROA	2.30%	Short Interest	5.94M	Perf YTD	-9.06%
Book/sh	63.96	P/C	10.51	EPS next 5Y	7.66%	ROE	3.82%	52W High	129.50 -21.62%	Perf Year	-2.41%
Cash/sh	9.66	P/FCF	22.93	EPS past 3/5Y	-33.21% 3.37%	ROIC	2.82%	52W Low	87.70 15.74%	Perf 3Y	-30.47%
Dividend Est.	0.27 (0.27%)	EV/EBITDA	16.81	Sales past 3/5Y	-10.38% -0.91%	Gross Margin	52.61%	Volatility	3.40% 2.93%	Perf 5Y	1.41%
Dividend TTM	0.28 (0.28%)	EV/Sales	5.11	EPS Y/Y TTM	78.53%	Oper. Margin	15.32%	ATR (14)	3.09	Perf 10Y	94.30%
Dividend Ex-Date	Jul 18, 2025	Quick Ratio	2.99	Sales Y/Y TTM	1.62%	Profit Margin	11.18%	RSI (14)	60.44	Recom	2.10
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	3.58	EPS Q/Q	53.57%	SMA20	3.78%	Beta	0.92	Target Price	116.81
Payout	11.63%	Debt/Eq	0.44	Sales Q/Q	2.28%	SMA50	7.31%	Rel Volume	0.54	Prev Close	102.40
Employees	11000	LT Debt/Eq	0.44	Earnings	Jul 28 BMO	SMA200	-7.04%	Avg Volume	1.25M	Price	101.50
IPO	Jul 06, 1965	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.46% 0.61%	Trades		Volume	676,357	Change	-0.88%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-25	Upgrade	UBS	Neutral → Buy	$115
Jan-10-25	Downgrade	Bernstein	Outperform → Mkt Perform	$130
Dec-13-24	Upgrade	BofA Securities	Neutral → Buy	$138
Oct-15-24	Upgrade	Barclays	Equal Weight → Overweight	$125 → $140
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$130
Jul-08-24	Initiated	Leerink Partners	Outperform	$125
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	UBS	Buy → Neutral	$105 → $125
Jan-04-24	Upgrade	Evercore ISI	In-line → Outperform	$88 → $125
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$95
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Sep-28-23	Initiated	Bernstein	Outperform	$133
Jul-19-23	Initiated	Raymond James	Outperform	$145
May-23-23	Resumed	Goldman	Buy	$150

Show Previous Ratings

Jul-11-25 12:03AM	3 Reasons to Sell RVTY and 1 Stock to Buy Instead (StockStory)
Jul-07-25 08:00AM	Revvity to Hold Earnings Call on Monday, July 28, 2025 (Business Wire)
Jul-03-25 12:37AM	3 Low-Volatility Stocks in the Doghouse (StockStory)
Jun-30-25 07:20AM	5 Insightful Analyst Questions From Revvity's Q1 Earnings Call (StockStory)
Jun-27-25 10:25AM	Revvity price target lowered to $110 from $116 at BofA (TipRanks)
11:13AM	Loading…
Jun-24-25 11:13AM	Is Revvity Stock Underperforming the Dow? (Barchart)
Jun-05-25 11:31AM	Pediatrix Medical Group (MD) Down 3.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-02-25 08:00AM	Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows (Business Wire)
May-23-25 10:47AM	RVTY Stock Falls Despite the Latest Launch of Automated Instrument (Zacks)
May-19-25 05:00PM	AstroNova Sends Letter to Shareholders Highlighting Growth Strategy and Strength of Board (Business Wire)
08:00AM	Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing (Business Wire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -5.88%
May-06-25 12:35AM	3 S&P 500 Stocks in the Doghouse (StockStory)
May-01-25 12:40AM	1 Safe-and-Steady Stock with Exciting Potential and 2 to Avoid (StockStory)
Apr-30-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
05:57AM	Loading…
Apr-29-25 05:57AM	Company News for Apr 29, 2025 (Zacks)
03:02AM	Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... (GuruFocus.com)
01:20AM	Q1 2025 Revvity Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-28-25 01:18PM	RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up (Zacks)
11:49AM	Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:13AM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:47AM	Biotech Firm Revvity Reports Better-Than-Expected Earnings (Investopedia)
09:30AM	Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:32AM	Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook (Reuters)
07:15AM	Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:09AM	Revvity: Q1 Earnings Snapshot (Associated Press Finance)
06:06AM	Revvity (NYSE:RVTY) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations (StockStory)
06:00AM	Revvity Announces Financial Results for the First Quarter of 2025 (Business Wire)
Apr-27-25 03:01AM	Revvity (RVTY) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-25-25 12:10PM	Why Revvity (RVTY) Could Beat Earnings Estimates Again (Zacks)
08:00AM	Loading…
08:00AM	Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely? (Zacks)
Apr-24-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
07:45AM	Bretton Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-23-25 10:01AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-21-25 10:00AM	Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline (Zacks)
Apr-10-25 01:31PM	Analyst Report: Revvity, Inc. (Morningstar Research) -8.21%
Apr-03-25 08:00AM	Revvity to Hold Earnings Call on Monday, April 28, 2025 (Business Wire) -5.59%
05:21AM	FDA approves Revvitys Auto-Pure platform and tuberculosis test combo (Medical Device Network)
Apr-02-25 08:00AM	Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test (Business Wire)
07:47AM	Here's Why You Should Retain Revvity Stock in Your Portfolio for Now (Zacks)
Mar-21-25 12:53PM	Revvity Stock Tumbles Despite Expanding Genomics England Alliance (Zacks)
Mar-20-25 08:13PM	Analyst Report: Revvity, Inc. (Morningstar Research)
01:00PM	Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England (Business Wire)
Mar-03-25 08:00AM	Revvitys EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay (Business Wire)
04:03AM	Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks (StockStory)
Feb-28-25 04:08AM	3 Reasons to Sell RVTY and 1 Stock to Buy Instead (StockStory)
Feb-26-25 08:32AM	Do Options Traders Know Something About Revvity (RVTY) Stock We Don't? (Zacks)
Feb-20-25 12:30PM	Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group (Business Wire)
08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Feb-18-25 10:18AM	Bretton Fund: Revvity (RVTY) Has Been On A Roller Coaster Ride The Last Few Years (Insider Monkey)
Feb-01-25 02:03AM	Revvity Inc (RVTY) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ... (GuruFocus.com)
12:00AM	Q4 2024 Revvity Inc Earnings Call (Thomson Reuters StreetEvents)
Jan-31-25 03:48PM	Revvity (NYSE:RVTY) Reports Q4 In Line With Expectations (StockStory)
03:10PM	Analyst Report: Revvity, Inc. (Morningstar Research)
09:30AM	Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:10AM	Revvity (RVTY) Surpasses Q4 Earnings Estimates (Zacks)
06:19AM	Revvity: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 (Business Wire)
Jan-24-25 12:27PM	Alphabet, Uber, Applied Materials, and 19 Other Picks From the Barrons Roundtable (Barrons.com)
10:00AM	Revvity (RVTY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-23-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
12:10PM	Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-13-25 04:31PM	S+P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast (Investopedia) +7.74%
08:00AM	Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing (Business Wire)
Jan-12-25 05:00PM	Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance (Business Wire)
Jan-10-25 11:37AM	Revvity wins FDA clearance for ChLIA assay in free testosterone measurement (Medical Device Network)
08:00AM	Revvity Announces FDA Clearance for First Automated Free Testosterone Test (Business Wire)
Jan-09-25 05:00AM	No time to waste: Revvity CFO Max Krakowiak (CFO.com)
Dec-17-24 08:00AM	Revvity to Present at J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 01:57PM	Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst (Benzinga)
Dec-04-24 11:30AM	Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report? (Zacks)
Nov-26-24 06:35AM	Revvity price target lowered to $135 from $140 at Barclays (TipRanks)
Nov-20-24 08:00AM	Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK (Business Wire)
Nov-19-24 08:00AM	Scale Biosciences and Revvitys BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells (Business Wire)
08:00AM	Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 08:00AM	Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation (Business Wire)
Nov-05-24 02:02AM	Revvity Inc (RVTY) Q3 2024 Earnings Call Highlights: Strong EPS and Cash Flow Amid Market Challenges (GuruFocus.com)
12:55AM	Q3 2024 Revvity Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-04-24 12:22PM	Analyst Report: Revvity, Inc. (Morningstar Research)
09:30AM	Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings (Zacks)
07:10AM	Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:09AM	Revvity: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Third Quarter of 2024 (Business Wire)
Oct-28-24 10:01AM	Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline (Zacks)
Oct-24-24 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
Oct-22-24 09:00AM	Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories (Business Wire)
08:00AM	Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report (Business Wire)
Oct-15-24 06:00AM	Revvity Ramps Up R&D Spending Since PerkinElmer Split (The Wall Street Journal)
Oct-09-24 05:18PM	Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... (GuruFocus.com)
Oct-07-24 08:00AM	Revvity To Hold Earnings Call on Monday, November 4, 2024 (Business Wire)
Oct-02-24 08:00AM	Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene (Business Wire)
Aug-21-24 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Aug-08-24 01:06AM	Decoding Revvity Inc (RVTY): A Strategic SWOT Insight (GuruFocus.com)
12:15AM	Bionano Genomics (BNGO) Q2 2024 Earnings Call Transcript (Motley Fool)
Jul-29-24 11:33PM	Q2 2024 Revvity Inc Earnings Call (Thomson Reuters StreetEvents) +9.07%
07:09PM	Analyst Report: Revvity, Inc. (Morningstar Research)
05:11PM	S&P 500 Gains and Losses Today: Onsemi Stock Jumps as Car Industry Drives Sales Beat (Investopedia)
12:19PM	Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised (Zacks)
10:48AM	Diagnostic Products Demand Boosts Profit and Sales at Revvity (Investopedia)
10:38AM	Life Science Firm Revvity Lifts Annual Profit Forecast On Strong Q2 Performance (Benzinga)

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McMurry-Heath Michelle	Director	May 29 '25	Sale	92.17	600	55,299	4,833	May 30 04:06 PM
McMurry-Heath Michelle	Director	May 29 '25	Proposed Sale	92.17	600	55,299		May 29 02:23 PM
McMurry-Heath Michelle	Director	Feb 06 '25	Sale	119.49	1,970	235,395	3,021	Feb 07 04:05 PM
McMurry-Heath Michelle	Director	Feb 06 '25	Proposed Sale	119.49	1,970	235,395		Feb 06 03:27 PM
Goldberg Joel S	Please See Remarks	Jan 30 '25	Option Exercise	81.29	15,170	1,233,169	48,570	Jan 31 04:05 PM
Goldberg Joel S	Please See Remarks	Jan 30 '25	Sale	126.73	15,170	1,922,513	33,400	Jan 31 04:05 PM
Goldberg Joel S	Officer	Jan 30 '25	Proposed Sale	126.73	15,170	1,922,555		Jan 30 04:05 PM
Vohra Tajinder S	Please See Remarks	Jan 07 '25	Option Exercise	81.29	5,492	446,445	25,144	Jan 08 04:05 PM
Vohra Tajinder S	Please See Remarks	Jan 07 '25	Sale	116.81	5,492	641,543	19,652	Jan 08 04:05 PM
Vohra Tajinder S	Officer	Jan 07 '25	Proposed Sale	116.81	5,492	641,539		Jan 07 04:58 PM
Singh Prahlad R.	Please See Remarks	Dec 02 '24	Option Exercise	81.29	18,365	1,492,891	108,560	Dec 03 04:05 PM
Singh Prahlad R.	Please See Remarks	Dec 02 '24	Sale	116.22	18,365	2,134,366	90,195	Dec 03 04:05 PM
Singh Prahlad R.	Officer	Dec 02 '24	Proposed Sale	115.79	18,365	2,126,483		Dec 02 10:55 AM
Vohra Tajinder S	Please See Remarks	Oct 09 '24	Sale	121.73	2,154	262,202	19,652	Oct 10 04:05 PM
Vohra Tajinder S	Officer	Oct 09 '24	Proposed Sale	121.73	2,154	262,199		Oct 09 04:21 PM
Vohra Tajinder S	Please See Remarks	Oct 08 '24	Sale	122.59	2,154	264,057	21,806	Oct 09 04:05 PM
Vohra Tajinder S	Please See Remarks	Oct 07 '24	Sale	122.09	2,153	262,853	23,960	Oct 09 04:05 PM
Vohra Tajinder S	Officer	Oct 08 '24	Proposed Sale	122.59	2,154	264,066		Oct 08 04:42 PM
Vohra Tajinder S	Officer	Oct 07 '24	Proposed Sale	122.09	2,153	262,855		Oct 07 04:10 PM
MICHAS ALEXIS P	Director	Aug 15 '24	Sale	118.62	850	100,827	7,770	Aug 16 04:05 PM
MICHAS ALEXIS P	Officer	Aug 15 '24	Proposed Sale	117.65	850	100,000		Aug 15 09:53 AM
Goldberg Joel S	Please See Remarks	Aug 07 '24	Sale	117.86	3,500	412,507	33,400	Aug 08 04:05 PM
Goldberg Joel S	Officer	Aug 07 '24	Proposed Sale	117.86	3,500	412,514		Aug 07 04:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVTY

Revvity Inc

Upgrade your FINVIZ experience